Study identifies key risk factors driving MASLD across populations
Background and aims Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population. The…
Novel biosensing platform provides quantitative graded evaluation of mild to severe liver injury
Real-time monitoring of key biomarkers is a critical prerequisite for early disease diagnosis and personalized therapy. Early detection…